Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B. Westritschnig K, et al. Among authors: jilma b. Hum Vaccin Immunother. 2014;10(1):170-83. doi: 10.4161/hv.26565. Epub 2013 Sep 24. Hum Vaccin Immunother. 2014. PMID: 24064511 Free PMC article. Clinical Trial.
Product review on the JE vaccine IXIARO.
Firbas C, Jilma B. Firbas C, et al. Among authors: jilma b. Hum Vaccin Immunother. 2015;11(2):411-20. doi: 10.4161/21645515.2014.983412. Hum Vaccin Immunother. 2015. PMID: 25621812 Free PMC article. Review.
Chikungunya vaccines in development.
Schwameis M, Buchtele N, Wadowski PP, Schoergenhofer C, Jilma B. Schwameis M, et al. Among authors: jilma b. Hum Vaccin Immunother. 2016 Mar 3;12(3):716-31. doi: 10.1080/21645515.2015.1101197. Hum Vaccin Immunother. 2016. PMID: 26554522 Free PMC article. Review.
Safety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial.
Schwameis M, Roppenser B, Firbas C, Gruener CS, Model N, Stich N, Roetzer A, Buchtele N, Jilma B, Eibl MM. Schwameis M, et al. Among authors: jilma b. Lancet Infect Dis. 2016 Sep;16(9):1036-1044. doi: 10.1016/S1473-3099(16)30115-3. Epub 2016 Jun 10. Lancet Infect Dis. 2016. PMID: 27296693 Clinical Trial.
Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A. Tauber E, et al. Among authors: jilma b. J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. J Infect Dis. 2008. PMID: 18588481 Clinical Trial.
554 results